[Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology].
In order to understand tumour biology in its complexity, it is necessary to investigate the proteomics in addition to the DNA and RNA level. SELDI-TOF-MS represents a new technology allowing a highly sensitive high-throughput analysis to detect specific protein profiles. In renal cancer, it was possible to define specific protein patterns in serum. Several proteins have been identified, i.e. serum amyloid alpha (SAA). Analysis of tumour tissues leads to a better understanding of tumour biology and provides the basis for differential classification and evaluation of prognosis. Investigation of the proteome concerning therapy results opens up the possibility of assessing downstream effects on the one hand and identifying biomarkers for selection of patients and therapy monitoring on the other hand. This review presents the first results for renal cancer.
Junker
K
K
Klinik für Urologie, Universitätsklinik der FSU, Jena. kerstin.junker@med.uni-jena.de
von Eggeling
F
F
Müller
J
J
Steiner
T
T
Schubert
J
J
D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000628:therapy; D019295:Computational Biology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000628:therapy; D011379:Prognosis; D040081:Protein Array Analysis
D005819:Genetic Markers